{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:53:23Z","timestamp":1781852003401,"version":"3.54.5"},"reference-count":15,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15674","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:00:51Z","timestamp":1780059651000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors for\u00a0invasive mucinous adenocarcinoma: A case series"],"prefix":"10.3892","volume":"32","author":[{"given":"Tatsuya","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mitsumura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiyu","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakahama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nei","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Uruga","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyo","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"key20260619091819_b1-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20260619091819_b2-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann Oncol"},{"key":"key20260619091819_b3-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: A systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20260619091819_b4-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.21037\/tcr.2019.11.02","article-title":"Invasive mucinous adenocarcinoma of the lung","volume":"8","author":"Xu","year":"2019","journal-title":"Transl Cancer Res"},{"key":"key20260619091819_b5-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"e0307580","DOI":"10.1371\/journal.pone.0307580","article-title":"Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma","volume":"19","author":"Liang","year":"2024","journal-title":"PLoS One"},{"key":"key20260619091819_b6-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"116058","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"key20260619091819_b7-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1186\/s12885-021-08472-6","article-title":"Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung","volume":"21","author":"Jang","year":"2021","journal-title":"BMC Cancer"},{"key":"key20260619091819_b8-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00432-024-05931-y","article-title":"The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung","volume":"150","author":"Kim","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20260619091819_b9-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"17588359241293401","DOI":"10.1177\/17588359241293401","article-title":"Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG\/NCI experience: Invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)","volume":"16","author":"Chae","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"key20260619091819_b10-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"key20260619091819_b11-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1016\/j.cllc.2020.05.014","article-title":"Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-Negative, EGFR\/ALK-negative lung adenocarcinoma: A propensity score matched pairs analysis","volume":"21","author":"Frost","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"key20260619091819_b12-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20260619091819_b13-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41698-025-00953-2","article-title":"Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A","volume":"9","author":"Yanada","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"key20260619091819_b14-ol-32-1-15674","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2169\/internalmedicine.52.0766","article-title":"A favorable response to cisplatin, pemetrexed and bevacizumab in two cases of invasive mucinous adenocarcinoma formerly known as pneumonic-type mucinous bronchioloalveolar carcinoma","volume":"52","author":"Yamakawa","year":"2013","journal-title":"Intern Med"},{"key":"key20260619091819_b15-ol-32-1-15674","first-page":"192","article-title":"Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review","volume":"9","author":"Sun","year":"2018","journal-title":"Mol Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:18:25Z","timestamp":1781849905000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15674","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}